Immunotherapy options UK

Immunotherapy is a group of treatments that work by helping the immune system recognise and attack disease, most commonly certain cancers. Rather than directly killing abnormal cells like chemotherapy, it stimulates or redirects the body's own immune defences, and different drug classes (such as checkpoint inhibitors) work in different ways.

Immunotherapy is usually considered for specific cancer types and stages where evidence shows it can improve outcomes, sometimes alongside surgery, chemotherapy or radiotherapy. The decision depends on the tumour type, its biological markers, and how it has responded to other treatments, so it is made by a specialist oncologist based on your individual case.

Preparation usually involves blood tests, imaging and a review of your current medications, since some drugs and pre-existing autoimmune conditions can affect suitability. Your oncology team will give you specific instructions, and it is worth being honest about any other conditions or supplements you take.

Most immunotherapy is given as an intravenous infusion in a clinic or day unit, typically over a few weeks between sessions, and you are usually monitored during and shortly after each session. Some regimens are combined with other cancer treatments, and your team will explain the specific schedule for your drug.

Because it activates the immune system, immunotherapy can cause the immune system to attack healthy tissue as well as cancer cells, leading to side effects that can affect the skin, gut, lungs, liver or hormone glands. These range from mild to serious, so any new symptoms should be reported to your care team promptly rather than waited out.

Response is usually assessed with scans and blood markers at set intervals, often every couple of months, since the immune system can take time to act and some scans can look temporarily worse before improving. Your oncologist will interpret these results in the context of your specific cancer.

If scans and markers show the disease is progressing, or side effects become difficult to manage, your oncologist will discuss alternative treatments, dose adjustments, or supportive care options. Treatment plans are regularly reviewed and adapted rather than fixed, so this is a normal part of ongoing cancer care.

Immunotherapy has transformed outcomes for a number of cancers, but response varies considerably between individuals and tumour types, and it does not work for everyone. Biomarker testing can help predict likely benefit, though it is not a guarantee, which is why ongoing monitoring is so important.

You can book a consultation with a private consultant oncologist, often without needing a GP referral, who can review your diagnosis and discuss whether immunotherapy is a suitable option. Private appointments are typically available within days, giving you a dedicated specialist opinion alongside any NHS care you are receiving.